Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

October 28, 2022

Study Completion Date

November 1, 2022

Conditions
Moderate to Severe Psoriasis
Interventions
BIOLOGICAL

JS005 (recombinant humanized monoclonal antibody against IL-17A)

Subcutaneous injection

BIOLOGICAL

JS005 placebo

Subcutaneous injection

Trial Locations (22)

100039

Chinese PLA General Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100191

Peking University Third Hospital, Beijing

102218

Beijing Tsinghua Changgung Hospita, Beijing

130061

First Hospital of Jilin University, Changchun

150086

Second Affiliated Hospital of Harbin Medical University, Haerbin

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

200050

Shanghai Skin Disease Hospital, Shanghai

210042

Dermatology Hospital, Chinese Academy of Medical Sciences, Nanjing

212001

Affiliated Hospital of Jiangsu University, Zhenjiang

250022

Dermatology Hospital affiliated to Shandong First Medical University, Jinan

250063

Qilu Hospital of Shandong University, Jinan

300001

The First Affiliated Hospital of Shanxi Medical University, Taiyuan

300052

Tianjin Medical University General Hospital, Tianjin

300120

Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin

310006

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

310014

Zhejiang Provincial People's Hospital, Hangzhou

330008

The Second Affiliated Hospital of Nanchang University, Nanchang

400042

The First Affiliated Hospital of Chongqing Medical University, Chongqing

510080

Guangdong Provincial People's Hospital, Guangzhou

516006

Dermatology Hospital of Southern Medical University, Guangzhou

050030

The First Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT05344248 - Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing | Biotech Hunter | Biotech Hunter